Mural Oncology announces acquisition by XRA 5 Corp., effective December 5, 2025, with shareholder payments anticipated by December 19.
Quiver AI Summary
Mural Oncology plc announced that its arrangement with shareholders for the acquisition by XRA 5 Corp., a subsidiary of XOMA Royalty Corporation, became effective on December 5, 2025. Following this, the distribution of cash considerations to shareholders is expected to begin shortly and must be completed by December 19, 2025. Additionally, Mural's shares have been canceled from trading on the Nasdaq Global Market as of December 4, 2025. The press release includes disclaimers regarding forward-looking statements and outlines the responsibilities of various financial and legal advisers involved in the transaction, while also noting potential legal restrictions on the announcement's distribution in certain jurisdictions.
Potential Positives
- The acquisition by XRA 5 Corp. provides Mural shareholders with cash consideration, potentially enhancing shareholder value.
- The Scheme becoming effective indicates a significant strategic move for Mural, facilitating its transition under new ownership.
- Completion of the acquisition allows Mural to streamline its operations and align with XOMA Royalty's strategic goals, which could benefit stakeholders.
- The structured timeline for the distribution of cash consideration and cancellation of trading indicates a well-planned transition process, which may instill confidence among investors and stakeholders.
Potential Negatives
- Cancellation of Mural Shares' admission to trading on the Nasdaq Global Market suggests a significant loss of market presence and accessibility for shareholders.
- The announcement indicates an acquisition which may imply potential operational or structural changes that could affect the future direction and stability of Mural as a standalone entity.
- The reliance on forward-looking statements highlights uncertainties and risks that may concern investors about the company's future performance and financial health.
FAQ
What is the effective date of the arrangement involving Mural Oncology?
The effective date of the arrangement is December 5, 2025.
Who is acquiring Mural Oncology's shares?
XRA 5 Corp., a wholly-owned subsidiary of XOMA Royalty Corporation, is acquiring the shares.
When will cash consideration be distributed to Mural shareholders?
Cash consideration distribution is expected to commence as soon as practicable after December 5, 2025.
What happened to the trading of Mural shares on Nasdaq?
The admission of Mural shares to trading on the Nasdaq was cancelled on December 4, 2025.
Where can I find more information about the acquisition?
A copy of the announcement is available on Mural’s website at https://ir.muraloncology.com/.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$MURA Insider Trading Activity
$MURA insiders have traded $MURA stock on the open market 5 times in the past 6 months. Of those trades, 0 have been purchases and 5 have been sales.
Here’s a breakdown of recent trading of $MURA stock by insiders over the last 6 months:
- CAROLINE LOEW (Chief Executive Officer) sold 12,531 shares for an estimated $30,475
- ADAM D. CUTLER (Chief Financial Officer) sold 7,148 shares for an estimated $14,939
- MAIKEN KESON-BROOKES (See Remarks) has made 0 purchases and 2 sales selling 4,730 shares for an estimated $11,730.
- VICKI L GOODMAN (Chief Medical Officer) sold 5,036 shares for an estimated $10,474
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$MURA Hedge Fund Activity
We have seen 26 institutional investors add shares of $MURA stock to their portfolio, and 51 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ARMISTICE CAPITAL, LLC removed 1,722,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $4,253,340
- SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,323,877 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $2,740,425
- PROSIGHT MANAGEMENT, LP removed 900,000 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,862,999
- SOLAS CAPITAL MANAGEMENT, LLC removed 887,995 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $2,193,347
- ACORN CAPITAL ADVISORS, LLC removed 653,779 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,353,322
- OMERS ADMINISTRATION CORP added 511,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $1,057,770
- LMR PARTNERS LLP removed 500,000 shares (-96.8%) from their portfolio in Q3 2025, for an estimated $1,034,999
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ Mural ”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “ Scheme ”) pursuant to which XRA 5 Corp. (“ Sub ”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“ XOMA Royalty ”) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the “ Effective Date ”).
Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.
Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market occurred with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025.
Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the definitive proxy statement of Mural dated 23 September 2025 relating to the Acquisition, which also constitutes a scheme circular under Irish law.
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION
FOR IMMEDIATE RELEASE
Enquiries
Mural Oncology plc
[email protected]
Lucid Capital Markets, LLC (Financial Adviser to Mural)
570 Lexington Ave, 40th Floor
New York, NY 10022
Cautionary Note Regarding Forward-Looking Statements
Statements contained in this announcement regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “believe”, “will”, “may”, “would”, “could” or “should” or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding the expected timing of the payment of the consideration paid by Sub to Scheme Shareholders and the expected timing of the cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market.
These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: risks and uncertainties pertaining to Mural’s business, including those described in Mural’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) and definitive proxy statement filed with the SEC on 23 September 2025, as well as Mural’s subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.
Statements Required by the Irish Takeover Rules
The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.
Lucid, which is authorized and regulated by the SEC and the Financial Industry Regulatory Authority (“ FINRA ”) in the United States, is acting as financial adviser exclusively for Mural and for no one else in connection with the subject matter of this Announcement and will not regard any other person as its client in relation to the matters in this Announcement and will not be responsible to anyone other than Mural for providing the protections afforded to clients of Lucid or its affiliates, nor for providing advice in relation to any matter referred to in this Announcement. Neither Lucid nor any of its subsidiaries, affiliates or branches owes or accepts any duty, liability or responsibility whatsoever (whether direct, indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Lucid in relation to the matters in this Announcement, any statement or other matter or arrangement referred to herein or otherwise.
Davy Corporate Finance, which is authorized and regulated in Ireland by the Central Bank of Ireland, is acting exclusively for XOMA Royalty and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than XOMA Royalty for providing the protections afforded to clients of Davy Corporate Finance or for providing advice in connection with the matters referred to in this Announcement.
Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP are acting as legal advisers on U.S. and Irish law matters respectively to Mural, and Gibson, Dunn & Crutcher LLP and Mason Hayes & Curran LLP are acting as legal advisers on U.S. and Irish law matters respectively to XOMA Royalty and Sub.
General
The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.
Publication on a Website
In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural’s website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.